FORMULATION OF ASPIRIN TABLET USE IN BlOOD CLOTTING

DISEASE

PRESENTED BY
RESHAM KHAN

GUIDED BY
Miss. PALLAVI
(Assistant Professor)

SCHOOL OF PHARMACEUTICAL SCIENCES

JAIPUR NATIONAL UNIVERSITY
 INTRODUCTION
• Aspirin also has an anti-platelet effect by inhibiting the creation of thromboxane, which binds
platelet molecules together to generate a patch over damaged walls of blood vessels.
• Aspirin is used for long-term, at low doses, to prevent heart attacks.
• Aspirin tablets are obtained by wet Compression Method. The particles to be compressed
consist of one or more medicaments.
• They are intended for oral administration. Some tablets are swallowed whole or after being
chewed, some are dissolved or dispersion in water before administration and some are retained
in the mouth where the active ingredient is liberated.
OBJECTIVE

•The main objective of the design and manufacture of the compressed tablet is to deliver orally
correct amount of drug in the proper form over proper time and at desired location, so as to
have suitable chemical integrity protected at the point of its action.
•Aspirin lowers the risk of heart attack, stroke, or blood clot. It may also be used to treat mild to
moderate pain, inflammation, or arthritis.
 MATERIALS AND METHODS
S/ INGREDIENT QUANTITY QUANTITY
NO. GIVEN (FOR 1 TAKEN
TABLET 250 mg) (FOR 25
TABLET)
1. Aspirin 130mg 3.25gm
2. HPMC 50mg 1.2gm
3. Microcrystalline 70mg 1.8gm
cellulose
4. Stearic Acid + Talc 1mg + 5mg 0.02gm
+0.12gm
5. PVP 0.1gm 0.1gm

•Direct compression method:

•The direct compression method use the advanced technology from the term direct compression
this method can be defined as basically mixing and processing of formulation ingredient then
compressing into tablet .
•The tablet are obtained directly from the powder API or other excipients .
•The successful adaptation of this method has lead to a reduction in units of operation.
•Less machinery involvement and minimize processing time.
FORMULATION OF ASPIRIN TABLET
DRUG, FILLER,
DISINTEGRANT,
LUBRICANT, GLIDANT

BLENDING

COMPRESSION
 REFRENCES

1. Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. (September 2021).
"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice" . European
Heart Journal. 42 (34): 3227–3337.
2. Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al. (January 2018). "2017
ESC focused update on dual antiplatelet therapy in coronary artery disease developed in
collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery
disease of the European Society of Cardiology (ESC) and of the European Association for
CardioThoracic Surgery (EACTS)". European Heart Journal. 39 (3): 213–260.
3. . Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. (September 2016). "2016
ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients
With Coronary Artery Disease: A Report of the American College of Cardiology/American
Heart Association Task Force on Clinical Practice Guidelines" Journal of the American College
of Cardiology. 68 (10): 1082–115.